Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Acorda Therapeutics (ACOR) stock in Canada | $5.23

Own Acorda Therapeutics (ACOR) shares in just a few minutes.

Acorda Therapeutics, Inc
-$0.33 (-7.69%)

Acorda Therapeutics (ACOR) (ACOR) is a leading biotechnology business based in the US. It opened the day at $5.16 after a previous close of $5.19. During the day the price has varied from a low of $5.1046 to a high of $5.28. The latest price was $5.23 (25 minute delay). Acorda Therapeutics (ACOR) is listed on the NASDAQ and employs 167 staff. All prices are listed in US Dollars.

How to buy Acorda Therapeutics (ACOR) stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ACOR in this case.
  5. Research Acorda Therapeutics (ACOR) stocks. The platform should provide the latest information available.
  6. Buy your Acorda Therapeutics (ACOR) stocks. It's that simple.

How has Coronavirus impacted Acorda Therapeutics (ACOR)'s stock price?

Since the stock market crash in March caused by coronavirus, Acorda Therapeutics (ACOR)'s stock price has had significant positive movement.

Its last market close was $3.72, which is 59.14% up on its pre-crash value of $1.52 and 431.35% up on the lowest point reached during the March crash when the stocks fell as low as $0.7001.

If you had bought $1,000 worth of Acorda Therapeutics (ACOR) stocks at the start of February 2020, those stocks would have been worth $430.25 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,832.51.

Acorda Therapeutics (ACOR) stock price

Use our graph to track the performance of ACOR stocks over time.

Acorda Therapeutics (ACOR) stocks at a glance

Information last updated 2021-06-28.
Previous close$5.19
Change $0.04
Change % 0.7707%
Volume 194,057
Information last updated 2021-07-22.
52-week range$2.5344 - $8.66
50-day moving average $4.2569
200-day moving average $5.1301
Wall St. target price$10
Dividend yield N/A (0%)
Earnings per share (TTM) $6.132

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Acorda Therapeutics (ACOR) stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Acorda Therapeutics (ACOR) price performance over time

Historical closes compared with the last close of $5.23

1 month (2021-06-28) 5.23
3 months (2021-04-28) 5.23%

Is Acorda Therapeutics (ACOR) under- or over-valued?

Valuing Acorda Therapeutics (ACOR) stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics (ACOR)'s overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Acorda Therapeutics (ACOR)'s PEG ratio

Acorda Therapeutics (ACOR)'s "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics (ACOR)'s future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Acorda Therapeutics (ACOR) financials

Revenue TTM USD$153.7 million
Gross profit TTM USD$96.8 million
Return on assets TTM -7.64%
Return on equity TTM -49.35%
Profit margin -82.34%
Book value $21.781
Market capitalisation USD$43.7 million

TTM: trailing 12 months

How to short and sell Acorda Therapeutics (ACOR) stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ACOR.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 675,629 Acorda Therapeutics (ACOR) stocks held short by investors – that's known as Acorda Therapeutics (ACOR)'s "short interest". This figure is 15% down from 794,667 last month.

There are a few different ways that this level of interest in shorting Acorda Therapeutics (ACOR) stocks can be evaluated.

Acorda Therapeutics (ACOR)'s "short interest ratio" (SIR)

Acorda Therapeutics (ACOR)'s "short interest ratio" (SIR) is the quantity of Acorda Therapeutics (ACOR) stocks currently shorted divided by the average quantity of Acorda Therapeutics (ACOR) stocks traded daily (recently around 414496.3190184). Acorda Therapeutics (ACOR)'s SIR currently stands at 1.63. In other words for every 100,000 Acorda Therapeutics (ACOR) stocks traded daily on the market, roughly 1630 stocks are currently held short.

However Acorda Therapeutics (ACOR)'s short interest can also be evaluated against the total number of Acorda Therapeutics (ACOR) stocks, or, against the total number of tradable Acorda Therapeutics (ACOR) stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics (ACOR)'s short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 Acorda Therapeutics (ACOR) stocks in existence, roughly 60 stocks are currently held short) or 0.089% of the tradable stocks (for every 100,000 tradable Acorda Therapeutics (ACOR) stocks, roughly 89 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Acorda Therapeutics (ACOR).

Find out more about how you can short Acorda Therapeutics (ACOR) stock.

Acorda Therapeutics (ACOR) stock dividends

We're not expecting Acorda Therapeutics (ACOR) to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Acorda Therapeutics (ACOR) stocks ever split?

Acorda Therapeutics (ACOR) stocks were split on a 1:6 basis on 3 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics (ACOR) stocks – just the quantity. However, indirectly, the new 500% higher stock price could have impacted the market appetite for Acorda Therapeutics (ACOR) stocks which in turn could have impacted Acorda Therapeutics (ACOR)'s stock price.

Acorda Therapeutics (ACOR) stock price volatility

Over the last 12 months, Acorda Therapeutics (ACOR)'s stocks have ranged in value from as little as $2.5344 up to $8.66. A popular way to gauge a stock's volatility is its "beta".

ACOR.US volatility(beta: 0.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics (ACOR)'s is 0.6736. This would suggest that Acorda Therapeutics (ACOR)'s stocks are less volatile than average (for this exchange).

Acorda Therapeutics (ACOR) overview

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Stocks similar to Acorda Therapeutics (ACOR)

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site